Autism Spectrum Disorder Therapeutics Market 2027 Snapshot | Industry Predict a Long-Term Growth at 10.9% CAGR by Revenue USD 5,225.5 Million | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Get Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables and Figures) of Autism Spectrum Disorder Therapeutics, https://www.coherentmarketinsights.com/insight/request-pdf/2643

Global Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  2,285.5 million in 2019 and is estimated to exhibit a CAGR of 10.9% over the forecast period (2019-2027).

The increasing number of investigational researches and funding to support pharmacogenomics-based drug discovery are major factors that are expected to drive growth of the autism spectrum disorder therapeutics market over the forecast period.  Moreover, several key players are focusing on receiving regulatory approvals to investigate novel drugs for the treatment of ASD. For instance, in January 2018, Roche announced that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for its investigational oral medicine balovaptan, a vasopressin 1a (V1a) receptor antagonist for individuals with ASD. Balovaptan demonstrated potential to improve social interaction and communication in people with ASD. Similarly, in May 2018, the U.S. FDA granted fast track designation for Yamo Pharmaceuticals’ investigational drug L1-79, a tyrosine hydroxylase inhibitor intended to diminish the socialization and communication symptoms in individuals with ASD. L1-79 demonstrated potential to address an unmet medical need for treatment of core symptoms of ASD.

Moreover, increasing funding for the research of ASD drugs is expected to drive the market growth over the forecast period. For instance, in June 2018, Innovative Medicines Initiative funded US$ 132 million to a research grant titled Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials), which is academically co-led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London and F. Hoffmann-La Roche, Basel.

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2643

Fuerthermore, key players in the autism spectrum disorder therapeutics market are focusing on adopting collaboration and partnership strategies to atrengthen their position in the global market. For instance, in 2017 Servier Laboratories Ltd. and Neurochlore signed an exclusive licensing agreement to develop and market bumetanide for pediatric autism in Europe. Under the agreement, Servier Laboratories Ltd. will develop and market the product in Europe and Neurochlore will retain these rights for the U.S. market.

Additionally, government organizations are focusing on piloting workshops for parents and caregivers of children with developmental disorders, which is further expected to augment ASD therapeutic market growth over the forecast period. For instance, a workshop conjointly led by Pan American Health Organization, World Health Organization, and Autism Speaks is organized in the month of August each year, in Buenos Aires, Argentina, to teach skills and raise awareness about autism and its preventive measures.

Browse 146 Market Data Tables and 30 Figures spread through 308 Pages and in-depth TOC on “Global Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2027”

To know the latest trends and insights related to Autism Spectrum Disorder Therapeutics Market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/autism-spectrum-disorder-therapeutics-market-to-surpass-us-3666-million-by-2026-1407

Key Takeaways of the Autism Spectrum Disorder Therapeutics Market:

• The global autism spectrum disorder therapeutics market is expected to exhibit a CAGR of 10.9% over the forecast period (2019-2027), attributed to increasing drug approvals, investigational studies, and funding
• On the basis of drug type, Aripiprazole segment is expected to account for major market share, in terms of revenue over the forecast period, attributed to increasing production of generics of Aripiprazole. For instance, in April 2015, the U.S. Food and Drug Administration (FDA) approved the pharmaceutical companies Alembic, Hetero Labs, Teva, and Torrent for manufacturing the generic version of Bristol-Myers Squibb’s Abilify oral tablets.
• Key players operating in the global autism spectrum disorder therapeutics market include F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.